

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.*

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities referred to herein will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act (“Regulation S”)), except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the U.S. Securities Act. No public offering of securities is to be made by the Company (as defined herein) in the United States.*



**BIOSTIME INTERNATIONAL HOLDINGS LTD.**

**合生元國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 01112)**

**SUPPLEMENTAL ANNOUNCEMENT  
AND  
RESUMPTION OF TRADING**

This announcement is made by Biostime International Holdings Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 6 June 2016, 15 June 2016, 16 June 2016 and 22 June 2016 in relation to the Senior Notes Issue (the “**Previous Announcements**”). All terms used herein have the same meaning as defined in the Previous Announcements, unless otherwise defined.

In connection with the Senior Notes Issue, there is certain financial information regarding the Group amongst the information that was previously contained in the offering memorandum attached to the overseas regulatory announcement made by the Company on 22 June 2016 that the Company would like to disclose by including such information in an announcement. An extract of such information is attached to this announcement (“**Other Information**”).

Save as disclosed in the Previous Announcements and this announcement, the Company is not aware of any information which must be announced to avoid a false market in the Company’s securities or of any inside information that is required to be disclosed under Part XIVA of the Securities and Futures Ordinance.

## **RESUMPTION OF TRADING**

At the request of the Company and as announced on 23 June 2016, trading in the shares (stock code: 01112) and the debt securities (stock code: 06024) of the Company on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) was halted with effect from 9.00 a.m. (Hong Kong time) on 23 June 2016 pending the release of this announcement. An application has been made by the Company to the Stock Exchange for the resumption of trading in the shares (stock code: 01112) and debt securities (stock code: 06024) of the Company with effect from 9.00 a.m. (Hong Kong time) on 24 June 2016.

By Order of the Board  
**Biostime International Holdings Limited**  
**Mr. Luo Fei**  
*Chairman*

Hong Kong, 24 June 2016

*As at the date of this announcement, the executive Directors of the Company are Mr. Luo Fei and Mr. Radek Sali; the non-executive Directors of the Company are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive Directors of the Company are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.*

## Other Information

### Illustrative financial information

In order to illustrate the effects of the Company's acquisition of 83% of the share capital of Swisse Wellness Group Pty Ltd ("**Swisse**"), and the financing related thereto (the "**Acquisition**") which was completed on 30 September 2015, the Company has prepared certain financial information on an unaudited pro forma basis to present the profit for each relevant period of the Company and its subsidiaries (the "**Group**") on the basis of the actual historical performance of the Group and Swisse for the relevant periods and assuming that the Acquisition had taken place on 1 January 2015. Such information should be read together with the audited consolidated financial statements of the Group as of and for the years ended 31 December 2015, 2014 and 2013 as previously disclosed in the announcement published by the Company on the Stock Exchange on 6 April 2016, 1 April 2015 and 2 April 2014, respectively, and the unaudited interim condensed consolidated financial statements of the Group as of and for the three months ended 31 March 2016 as previously disclosed in the announcement published by the Company on the Stock Exchange on 6 June 2016. Such information addresses a hypothetical situation for illustrative purposes only, of the main potential impacts that may derive from the Acquisition and, therefore, does not represent the actual financial results of operations of the Group. Such information has not been prepared in accordance with the requirements of Regulation S-X under the U.S. Securities Exchange Act of 1934 or U.S. GAAP. Neither the adjustments nor the resulting pro forma financial information have been audited or reviewed in accordance with IFRS or U.S. GAAS. Such information should be read in conjunction with the historical consolidated financial statements and notes thereto of the Group and Swisse.

The profit for the year ended 31 December 2015 for the historical financial statements for the Group, which includes the results of operations of Swisse for the three months after September 30, 2015, and for Swisse, which represents the results of operations of Swisse for the nine months ended September 30, 2015, was RMB293.3 million and RMB43.7 million, respectively. After giving effect to certain adjustments relating to the Acquisition, the illustrative unaudited pro forma profit for the year ended 31 December 2015 for the Group was RMB214.9 million. The profit for the three months ended 31 March 2015 for the historical financial statements for the Group and for Swisse was RMB91.3 million and RMB81.5 million, respectively. After giving effect to certain adjustments relating to the Acquisition, the illustrative unaudited pro forma profit for the three months ended 31 March 2015 for the Group was RMB132.1 million. The profit for the 12 months ended 31 March 2016 for the historical financial statements for the Group, which includes the results of operations of Swisse for the six months after September 30, 2015 following the Acquisition and

represents the results of operations for the year ended 31 December 2015 plus the results of operations for the three months ended 31 March 2016 less the results of operations for the three months ended 31 March 2015 for the Group, and the losses for the six months ended 30 September 2015 for Swisse was RMB631.3 million and RMB37.8 million, respectively. After giving effect to certain adjustments relating to the Acquisition, the illustrative unaudited pro forma profit for the 12 months ended 31 March 2016 for the Group was RMB512.1 million.

### **Recent regulatory developments**

On 6 June 2016, the China Food and Drug Administration (國家食品藥品監督管理局) (the “CFDA”) released the Administrative Regulations for the Registration of Formula of Infant Milk Formula Powder Products (嬰幼兒配方乳粉產品配方註冊管理辦法), pursuant to which formulas of infant milk formula products sold on the Chinese market should be registered with the CFDA and each domestic formula manufacturer and offshore formula manufacturer that intends to export formula products into China may register up to nine formula products in three formula series (for stage 1 formula (0-6 months), stage 2 formula (6-12 months) and stage 3 formula (12-36 months)). The aforesaid registrations will be valid for a term of five years and should be renewed six months before expiry. The new regulation will be effective on 1 October 2016.

Pursuant to a prior statement from the Ministry of Finance, the registration deadline applicable to infant milk formula products imported through cross-border e-commerce has been postponed to 1 January 2018.